Document is current

Documents that mention this clinical trial

Vaccines for immunoprevention of DNA mismatch repair deficient cancers
https://doi.org/10.1136/jitc-2021-004416

Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA
https://doi.org/10.1136/jitc-2020-001065

1526 Nous-209 genetic vaccine encoding shared cancer neoantigens is safe and elicits robust immune response in healthy Lynch syndrome carriers: interim results from Phase 1 cancer interception trial
https://doi.org/10.1136/jitc-2023-sitc2023.1526

Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion
https://doi.org/10.1136/jitc-2021-003480

410 Phase I interim study results of Nous-209, an off-the-shelf immunotherapy, with pembrolizumab, for the treatment of tumors with a deficiency in mismatch repair/microsatellite instability (dMMR/MSI)
https://doi.org/10.1136/jitc-2021-sitc2021.410

Results of phase I-II bridging study for Nous-209, a neoantigen cancer immunotherapy, in combination with pembrolizumab as first line treatment in patients with advanced dMMR/MSI-h colorectal cancer.
https://doi.org/10.1200/jco.2023.41.16_suppl.e14665

New emerging targets in cancer immunotherapy: the role of neoantigens
https://doi.org/10.1136/esmoopen-2020-000684

Documents that mention this clinical trial

Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA
https://doi.org/10.1136/jitc-2020-001065

Cell therapy in sarcoma: current landscape and future directions
https://doi.org/10.1136/jitc-2025-013396

The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee
https://doi.org/10.1136/jitc-2025-013420